UNSPSC 51311804: Emedastine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C17H26N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9J1H7Y9OJV, chemically known as 1-methyl-4-(1-(2-ethoxyethyl)-1h-benzimidazo)-2-yl)(1,4)diazepane but generally known as emedastine, which bears US NIH Compound Identifier 3219. European Medicines Agency schedules Emedastine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06503MIG.

UNSPSC 51311804 Emedastine is a Commodity code that encompasses pharmaceutical products, but the recent state and local solicitations tagged under it diverge significantly from the code's nominal scope. The three opportunities on record involve naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and OTC products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). The issuing bodies include county health departments, state health and human services agencies, and multi-state cooperative purchasing alliances administering on behalf of participating jurisdictions. The work being solicited ranges from procurement of specific pharmaceutical inventories for quarterly delivery and storage to vendor capability assessments for alternative pharmacy benefit distribution models and supply-chain contracting structures. State and local governments under this code are buying both finished pharmaceutical products for direct use and access to vendor networks capable of managing large-scale, multi-jurisdiction pharmaceutical distribution under cooperative agreements.

Geographic activity centers on Florida, Texas, and Minnesota, with the Minnesota MMCAP procurement explicitly serving multiple participating states including Oregon. Representative recent opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026, response deadline April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements; and the Minnesota Department of Administration's MMCAP RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing multiple contracts for generic pharmaceuticals and OTC products with May 15, 2026 availability and July 1, 2026 effectiveness. The Seminole County opportunity requires E-Verify compliance, drug-free workplace certification, and specific insurance coverage; the MMCAP RFP weights price competitiveness at 75 percent and mandates cGMP and Drug Supply Chain Security Act certification. The code shows limited, geographically dispersed recent activity with mixed relevance to emedastine specifically.